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Abstract 
Metabolic syndrome (MetS) is a clustering of atherosclerotic cardiovascular disease 
(ASCVD) risk factors including central obesity, insulin resistance, dyslipidaemia, 
hypertension, and pro-inflammatory and pro-thrombotic states. 1t is aJso a precursor of 
type 2 diabetes mellitus (T2DM). Research continues to uncover the mechanical links of 
the pathogenesis of MetS as well as to discover new drugs to target the multiple 
metabolic and haemodynamic abnom1alities of MetS. The focus of tl1is thesis is on the 
investigation of two Chinese herbal medicines, Sugarid and SK0504, in the treatment of 
MetS and T2DM induced in C57BL/6J mice by high fat diet (HFD) feeding with or 
without streptozotocin (STZ) injection. 
The results described in Chapter 3 show that T2DM was induced in mice fed HFD when 
their blood glucose levels rose after the STZ injection. Treatment with a Chinese herbal 
product, Sugarid di.d not show any significant improvements of body and visceral fat 
weights, glucose metabolism, insulin sensitivity, and serum and liver lipid parameters in 
either MetS and T2DM models of mice. Therefore, the findings from this study do not 
support the notion of Sugar1d being a potential dntg in treatment of MetS and T2 OM. 
The purpose of Chapter 4 is to investigate the effects and mechanisms of a new herbal 
fommla, SK0504 in HFD fed mice. Treatment with SK0504 showed significant 
improvements of visceral fat weight, insulin sensitivity and some biochemical 
parameters. The findings of this study showed potential beneficial effects of SK0504 on 
MetS by its ability to target central obesity, insulin resistance and hyperlipidaemia. 
However, the hypothesised effects of SK0504 in targeting the multiple metabolic 
XI 
abnormalities of MetS were not obtained. The last chapter outlines possible avenues fo r 
further research in order to confinn any implications of the experimenta l findings 
reported in this thesis. 
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